- Trial Phase
- Phase 2b completed; Phase 3 pivotal program planned
- Time to Market
- At least 3-4 years, assuming Phase 3 success and regulatory filing
- Why 7/10
- The next hard catalyst is the initiation of the global Phase 3 pivotal program for GH001 in TRD, targeted for late 2026 (within ~3-4 months). This is the company's lead and essentially only value-driving asset, and the Phase 3 start represents a major derisking milestone following FDA Phase 3-ready confirmation. However, it is a program initiation, not a binary readout, capping the score at 7.
The next major catalyst is the initiation of the global Phase 3 pivotal program for GH001 in TRD, targeted for late 2026. Investors should watch for enrollment announcements and any FDA regulatory updates. The $200M ATM facility creates potential dilution overhang, but the strong cash position ($362.7M) and FDA alignment on Phase 3 readiness significantly de-risk the path forward. Any delay in Phase 3 initiation would be a negative signal.
Price Chart
Executive Summary
Mebufotenin (GH001) is GH Research PLC's lead drug candidate — an inhaled, aerosolized formulation of 5-MeO-DMT, a rapid-acting psychedelic being developed for treatment-resistant depression (TRD). A Phase 2b trial published in JAMA Psychiatry met its primary endpoint with a highly significant -15.5-point placebo-adjusted MADRS reduction (p<0.0001), showing a 57.5% Day 8 remission rate and 73% remission at 6 months in open-label extension completers. The FDA confirmed in July 2026 that the company's CMC and device plans appear Phase 3 ready. GH Research has $362.7M in cash and targets initiating a global Phase 3 pivotal program in late 2026. The stock trades at ~$28 with a mean analyst price target of ~$43 (42.5% implied upside) and a consensus of 16 Buy/Strong Buy ratings vs. 1 Hold and 0 Sell.
How It Works
Mebufotenin is an inhaled formulation of 5-MeO-DMT, a naturally occurring psychedelic compound that rapidly activates serotonin receptors (primarily 5-HT1A and 5-HT2A) in the brain. Unlike traditional antidepressants that take weeks to work, mebufotenin produces an intense but brief psychedelic experience (typically 15-30 minutes) that appears to rapidly reset neural circuits involved in mood regulation. It is administered as an aerosol via a breath-actuated inhaler, designed to deliver a consistent dose without the variability of other administration routes.
Trial Status
A Phase 2b trial in TRD (n=~80) met its primary endpoint with a -15.5-point placebo-adjusted MADRS reduction (p<0.0001) and was published in JAMA Psychiatry in March 2026. The study showed a 57.5% remission rate at Day 8 and 73% remission at 6 months in open-label extension completers. Two Phase 1 trials (UK aerosol device study and US IND-opening study) completed enrollment. Doses have been selected for the global Phase 3 pivotal program, which targets initiation in late 2026. The FDA confirmed in July 2026 that the company's CMC and device plans appear Phase 3 ready.
The Two-Sided Case
Upcoming Catalysts
- Initiation of global Phase 3 pivotal program for GH001 in TRD (targeted late 2026)
- Potential FDA regulatory updates on Phase 3 program design
- Enrollment updates from Phase 3 program
- Q3 2026 earnings report (expected November 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GH Research PLC 6-K GHRS ·Originating report